Trial Profile
COMPliance with Avonex PS in patients with relapsing-remitting MS
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 04 Jun 2015
Price :
$35
*
At a glance
- Drugs Interferon beta-1a (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms COMPASS
- Sponsors Biogen Idec
- 27 Jan 2012 Actual end date (Dec 2011) added as reported by ClinicalTrials.gov.
- 27 Jan 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2011 Planned end date changed from Feb 2011 to Feb 2012 as reported by ClinicalTrials.gov.